Are you in cardiology, hematology or another specialized field? Access interviews with various clinicians whose practice could bring them in contact with patients who may warrant referral to the REVERSE-IT trial.
Approximately 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria.